| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |